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Matrix pellets containing Sodium alginate (Kelton LV CR) at a level 
of 10, 20 and 30 %w/w was prepared by extrusion/spheronization 
technique. Sertraline hydrochloride was used as model drug and in 
vitro release profile of 12 h was targeted. Calcium chloride was used 
either by granulating the sodium alginate containing blend with 10% 
w/w solution or by pouring the wet pellets into saturated solution of 
calcium chloride. Tablets containing pellets were prepared by direct 
compression process. Acceptance value was used employed to 


















The study involves a newer approach of compression of matrix 
pellets into disintegrating tablet to overcome the rupture of polymer 
coat during compression of reservoir type pellets.  
In vitro drug release from alginate containing pellets was complete 
within 4 h and the desired release profile could be achieved only 
from pellets treated with calcium chloride. The drug release from the 
uncompressed pellet and compressed tablet was identical, as each 
pellet was behaving like a monolithic mini matrix system. Scanning 
electron micrographs of the tablet indicated the uniform distribution 
of the pellets within the diluent blend. Scanning electron 
micrographs of the pellets obtained after completion the dissolution 
test were found to be left with empty sac like structure releasing the 
drug indicating anomalous type drug release.  
Matrix pellets containing sodium alginate could be prepared by 
extrusion spheronization technique which can be an alternative 
approach in preparing disintegrating tablets from pellets.   
Keywords: Extrusion/spheronization, Matrix pellets, Acceptance 
value, MUPS Tablets. 
 
Introduction 
Multiple unit extended release dosage forms are 
becoming very popular dosage forms over 
single unit dosage forms because of their ability 
to spread uniformly in the gastrointestinal tract 
minimizing the plasma level variability and 
reduced risk of local irritation [1-2]. 
Conventional design of extended release 
systems involves coating of spherical pellets 
with polymer that regulates their drug release 
rate and extent. However, considering the high 
cost of the capsule shells and encapsulation 
difficulties, more emphasis has been given to 
compress these pellets into disintegrating 
tablets. Multi unit particulate system (MUPS) is 
a tablet dosage form wherein pellets are 
compressed into tablets along with appropriate 





excipients or cushioning agents in order to 
prevent the damage to the coating layer which 
regulates the drug release from the pellets. 
Polymers usually used to regulate the drug 
release from the pellets involves either 
cellulosic polymers or acrylic polymers 
[3].However, studies involving compression of 
pellets coated have reported the mechanical 
damage to the coating and loss of extended 
release properties [4] which could be due to the 
brittle nature of the film [5]. In contrary, drug 
release from the tablet was also slower from the 
pellets compressed at higher compression force 
due to fusion of pellets [6]. Various techniques 
were reported in minimizing the damage to the 
coat by suitably selecting the cushioning agents 
and maintaining the pellet size [7]. However 
recent studies involved use of polyethylene 
glycol as cushioning agent and compression the 
tablet at elevated temperature [8].  
 
In the present study extrusion/spheronization an 
established technique for making spherical 
pellets was employed to prepare matrix pellets. 
Various polymers have been explored in 
preparing the pellets using extrusion 
spheronization technique [9]. Sodium alginate, a 
natural polymer has been used in the drug 
delivery systems like monolithic matrix tablets 
and extended release coated dosage forms [10-
11]. As per the literature support from the 
granted patent publication US 6,899,896, 
sertraline hydrochloride (SRT) was used as 
model drug which is most commonly prescribed 
for depressive illness. As per the patent, 
increasing the sertraline dose beyond 50 mg, 
slow and prolonged release for about 12h would 
increase the patient compliance by reducing the 
side effects associated with the sertraline 
treatment at higher dose [12].  
 
The objective of this study was to investigate 
the possibility of producing the extended release 
matrix pellets by extrusion/spheronization 
technique using and Sodium alginate (Keltone® 
LV CR) and to evaluate the effect of calcium 
chloride treatment on in vitro release profile.  
To compress the matrix pellets into MUPS 
tablets and evaluate the effect on the in vitro 
drug release and uniformity of drug content. As 
per our literature review, though there were 
various techniques being adopted to protect the 
extended release coat rupture during 
compression of pellets, no studies involving 
preparation MUPS tablets from the matrix 
pellets using sodium alginate has been 
extensively evaluated. 
 
Materials and Methods 
Materials 
Sertraline was obtained from the Matrix 
Laboratories Ltd, India. Sodium alginate 
(Keltone® LVCR) was procured from ISP 
Corporation India. Calcium chloride and other 
excipients used in the pellet preparation and 
tablet compression were obtained from Matrix 
Laboratories Ltd, Hyderabad, India.  
 
Methods 
Preparation of Matrix type pellets by 
extrusion/spheronization 
Different formulations of matrix type pellets 
were prepared with a composition shown in 
Table 1. All the batches were of 2000 units of 
100 mg strength.  During the pellet preparation, 
dry powder mixture was prepared by mixing 
sertraline, microcrystalline cellulose in a 
laboratory scale Rapid mixer granulator [Allen 
Bradley 5L, USA] at slow impeller speed for 
about 10 min. The blend containing sodium 
alginate was granulated using water as 
granulating fluid. Additional water, if required 
was incorporated during granulation to obtain 
wet mass suitable for extrusion and obtaining 
the quality pellets in terms of roundness 
(visually observed). 
 
Appropriate quantity of the binding liquid and 
kneading time, which gave suitable wet mass for 
extrusion, was determined by trial and error 
process. The wet mass was extruded through a 
screen extruder [Multigran MG 55, Fugi Paudal 
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Co Ltd Japan.] equipped with a standard screen 
0.8 mm diameter aperture, and the rolls rotating 
at 30rpm. The extrudes were transferred to the 
spheronizer [QJ 230T-1, Fugi Paudal Co Ltd 
Japan.] equipped with a crosshatch plate [1mm] 
and processed at 850 rpm rotating speed for 
desired time (4-15 min). The resultant pellets 
were dried in a fluid bed dryer [Rapid dryer, 
Retsch, Germany] with an inlet air flow at 500C 
for about 20-30 min. The dried pellets were 
sifted through ASTM 20 mesh (841 µ) and 
retentions were discarded. The fines below 
ASTM Mesh # 40 (420 µ) were also not 
included. 
 
Table 1: Composition of extended release matrix pellets 
containing sodium alginate.  
COMPOSITION (MG) #F1 #F2 #F3
Sertralinea 112 112 112 
Microcrystalline Cellulose) 
Avicel PH102) 
176 144 112 
Sodium Alginate 32 64 96 
Water qs Qs Qs 
Total Weight (mg) 320 320 320 
a Weight of Hydrochloride salt equivalent to 100 mg 
sertraline base. qs-Quantity sufficient. 
 
Calcium chloride treatement of sodium 
alginate pellets 
Calcium ion complexation was carried out on 
sodium alginate containing composition using 
the two approaches. In one of the approaches, 
Sertraline, microcrystalline cellulose and 
sodium alginate containing blend (# F2) was 
granulated with 10% w/w solution of calcium 
chloride (CaCl2). In another approach, about 
320 g of the wet spheroids containing 20 %w/w 
sodium alginate was poured in to 500 ml 
saturated solution of Calcium chloride and 
allowed to form the gelatinous precipitate by 
chemical reaction between sodium alginate and 
calcium chloride on the surface of the pellets. 
The pellets were left under slow stirring for 
about 10 min and then removed by filtration and 
washed with distilled water and vacuum dried. 
 
 
Preparation of MUPS Tablets 
MUPS tablets were prepared by direct 
compression approach where 320g of calcium 
chloride treated pellets were mixed with 
microcrystalline cellulose (Avicel PH 102, 446 
mg, Avicel PH 101 200mg), polyethylene glycol 
(31g) and crospovidone (64g) in a laboratory 
scale blender [Conta Blender, Bowman & 
Archer] for 10 min. Finally, magnesium stearate 
(5g) passed through 250 µm sieve was added on 
to the mixture and blended for 5 min. The 
degree of filling of the blending vessel used was 
50% by volume to ensure proper mixing. The 
tablets of 1066± 50 mg were compressed using 
one set of 19.5mmX 9.5 mm capsule shaped, 
biconvex tooling on a 12 station automated 
single rotary compression machine [Smart 
Press, SRC 10i, Pacific Industries, India]. The 
compression machine is equipped to measure 
the compression forces applied on the blend. 
Considering the criticality of the compression, 
the machine speed was set to 10 rpm. Tablets 
were compressed at different compression 
forces ranging 2-6kN in order to obtain the 
tablets with crushing strength ranging between 
80 to 240 N.    
 
Characterization of Pellets and compressed 
tablets 
Density and Friability 
The bulk density was determined by pouring 
pellets into a previously weighed 10 ml 
graduated glass cylinder and the weight of the 
pellets to occupy 10 ml volume was noted. The 
bulk density was calculated by the ratio of 
weight to the occupied volume.  
Friability was measured using Electrolab 
Friability testing apparatus [Electrolab Ltd, 
Mumbai, India] by tumbling 10 g of the pellets 
for 4 min at 25 rpm. The tested pellets were 
gently tapped on ASTM # 40mesh to remove 
the fines generated and the weight loss was 
measured. For testing the friability of the 
tablets, ten tablets were weighed on an 
analytical balance transferred to the friabilator 
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after removing the powdered dust and % weight 
lost during testing was calculated.  
 
Sphericity 
The Sphericity of the pellets was measured by 
the simplest approach described by Lovgren and 
Lundberg [13], by measuring the length and 
width of the two dimensional image of the 
pellets using optical microscope [Olympus 
BX55TF, Japan].  The shape factor was 
expressed as a % Sphericity, where 100 % 
corresponds to a perfect circle. The longest 
length and breadth of the pellets were measured 
accurately when the pellets were rested in their 
most stabile position. A frequency distribution 
of the percent ratio of length to breadth of 100 
pellets was calculated and the Sphericity (S) 
was expressed [14]. 
 
Hardness Testing 
The force required to fracture a tablet was 
measured using a tablet hardness tester [Dr 
Schleuniger, Pharmatron 8M]. Hardness of 10 
tablets from each formulation was reported as a 
range.  
 
Disintegration testing  
The disintegration time of the tablet was tested 
on 6 tablets using USP disintegration apparatus 
[Electrolab Disintegration Apparatus, India]. 
Distilled water was used as disintegration 
medium at 37 0C temperature. The time taken 
until no material from any of the tablets was left 
on the mesh was recorded. 
 
In vitro dissolution testing 
In vitro release study on the pellets and 
compressed tablets was performed using acetate 
buffer pH 4.5 in a dissolution test apparatus. 
[Electrolab, Mumbai, India]. The test employed 
900 ml of specified buffer at 37 0C, paddles 
rotating at 50 rpm. Sink conditions was kept 
through out the test. Samples were collected at 
1, 2, 4, 6, 8, 10 and 12 h intervals and analyzed 
by UV-Visible spectrophotometer [UV 2450, 
Shimadzu Corporation, Japan] at 273nm.  
Dissolution of pellets and MUPS tablets was 
conducted on 6 representative samples.   
 
Drug content analysis 
To determine the drug content, weight of the 
crushed pellets equivalent to 100mg of sertraline 
was weighed into a flask (1000ml) and extracted 
with minimum quantity of methanol and made 
up the volume with acetate buffer pH 4.5 and 
sonicated for about 30 min. UV absorbance of 
the solution filtered through 0.43µ filters was 
measured using UV-Visible spectrophotometer 
[UV 2450, Shimadzu Corporation, Japan] at 273 
nm (λmax).  To avoid the interference of the 
excipients, placebo blend was also treated 
similarly and kept as blank. Standard solution 
was prepared by weighing [Mettler Toledo, 
India] accurately 100 mg of sertraline and 
following the similar dilution procedure. From 
the absorbance of the test solution, the amount 
of drug in the solution was calculated.  
 
Acceptance Value 
Acceptance value is a test recommended by the 
pharmacopoeia for evaluating the content 
uniformity in the dosage forms [15]. As MUPS 
tablet involves compression of two varying 
density components together, achieving the 
content uniformity within the pharmacopoeial 
limits is a challenging task [16]. Hence 
Acceptance value was considered as a tool for 
evaluation of uniformity of the drug content was 
considered. The drug content of 10 individual 
tablets was measured with the method as 
described above. Acceptance value was 
calculated as per the equation below.   
 
      AV= |M-X| + kS (1) 
Where k is acceptability constant (k = 2.4 for 10 
tablets), S is standard deviation of assay values 
of 10 units, X is mean of the assay value. M =X 
when X value is between 98.5 -101.5%. M = 
98.5 if X value is below 98.5 and M =101.5 if X 
value is above 101.5. Absolute value for M-X to 
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Scanning electron microscopy 
In order to observe the distribution of pellets 
within diluent blend, scanning electron 
microscopy was used [Jeol, JSM 6380LV, 
Japan]. For this purpose, tablets were subjected 
to hardness testing and the broken tablet surface 
was focused. To understand the drug release 
mechanism, pellets obtained after completing 
the in vitro dissolution test (for 12 h) were 
collected separately by slowly decanting the 
dissolution media, dried and observed using 
scanning electron microscope.  
 
Results and Discussion  
Preparation of Matrix type pellets and effect 
of polymers 
In maintaining the drug release from the pellets 
after compression type, nature and amount of 
polymer plays major role. In most of the studies 
of compression of the coated pellets, showed 
damage to the coating with a loss of the 
extended release properties [17] and usually 
faster drug release was observed [18]. Hence, 
compression of matrix pellets into disintegrating 
tablet dosage form concept was arrived to 
address the issues pertaining to compression of 
reservoir type pellets coated with polymers for 
extended release of drug. In the present study 
commercially available sodium alginate was 
evaluated to develop matrix type pellets with 
extended drug release profile. The nature of the 
granules suitable for the extrusion was decided 
based on the preliminary experiments. The 
properties of the pellets prepared using 10%, 
20% and 30% w/w polymer are represented in 
the Table 2.  
 
Extrusion of blend containing higher level of 
polymer (30% w/w) through 0.8mm screen 
aperture was difficult and increase in 
spheronization time (12-15 min) was observed. 
Level of polymer beyond 30% w/w was not 
evaluated as it was generating lengthy extrudes 
leaving tackiness during extrusion. The 
spheronization process was continued until 
spherical pellets were observed. The drug 
release pattern from the pellets containing 
different level of sodium alginate was faster 
(Figure 1) with more than 85% of the drug 
release within 4h. The rapid dissolution from the 
pellets could be ascribed to surface erosion and 
formation of soluble hydrogel and wherein the 
drug release could happen due to both diffusion 




Table 2: Physical characterization data of extended release core pellets prepared by extrusion/spheronization process. 










# F1 10 Spherical 0.245 0.876 78 ± 4% 
# F2 20 Spherical 0.210 0.888 86 ± 5% 
Sodium Alginate 
# F3 30 Dumbbell-
Shaped 
0.220 0.877 72 ± 6% 
Calcium Chloride 
Granulation  
# F4 20 Spherical 0.195 0.869 85 ± 6% 
Calcium Chloride 
Treated 




























Figure 1: In vitro dissolution profiles of sertraline from 
pellets containing  (-♦-) 10%w/w, (-■-) 20%w/w and (-
▲-) 30%w/w Keltone® LV CR. 
 
Effect of calcium chloride 
Treating the sodium alginate containing pellets 
with calcium chloride for obtaining the extended 
drug release has been studied [19]. Similarly in 
our study, calcium chloride treated pellets could 
extend the release of sertraline for about 12h 
compared to sodium alginate containing pellets.  
Cross-linking of the calcium ions generates 
insoluble calcium alginate layer on the surface 
of the beads reducing the entry of the 
dissolution media into the pellets. Hence the 
drug release from these beads was extended to 
the desired profile as illustrated in Figure 2. 
Though in vitro release from the pellets 
obtained by granulation with the 10% solution 
of calcium chloride was slower compared to 
plain sodium alginate containing pellets, the 
release was significantly faster compared to the 
pellets treated with saturated calcium chloride 
solution. The difference in the release profile 
can be attributed lower level of the calcium 
chloride which may produce incomplete and 
discontinuous complexation during granulation 
using the calcium chloride solution. Treating 
with the saturated calcium chloride produces 
uniform gelatinous insoluble mass on the 
surface of the each pellet which would be 
helpful in extending the drug release for a 
























Figure 2: In vitro dissolution profiles of sertraline from 
pellets containing  (-♦-) 20%w/w plain sodium alginate, (-
▲-) granulated with calcium chloride granulated pellets 
and (-■-) Calcium chloride treated pellets. 
 
Pellet Characterization 
Pellets obtained with all these polymers showed 
comparable density, sphericity and friability as 
compiled in Table 2. The shape of the pellets 
obtained was varied from spherical to elongate 
spherical or dumbbell shape in some cases. 
Pellets were almost spherical in nature where in 
the sphericity value was ranging from of 72 % 
to 88%.  
 
Compression of core pellets into MUPS 
tablets. 
Based on the release profile of the pellets 
observed, only pellets treated with saturated 
solution of  calcium chloride was considered for 
compression into MUPS tablets. These tablets 
are intended to disintegrate into discrete pellets 
in the gastrointestinal tract to release the drug 
from individual pellets. Due to differences in the 
size and density of pellets and the excipients, 
weight variation and content uniformity 
problems are regularly observed during 
compression of pellets. However, by selecting a 
narrow size distribution pellets together with 
excipients of similar size, shape would produce 
tables with uniform content [16]. Hence in our 
study, pellets fraction between ASTM # 20 




Pai et al. International Journal of Drug Delivery 3 (2011) 329-339 
 
used. Direct compression approach was used to 
obtain disintegrating tablets using 
microcrystalline cellulose for reducing the 
damage, crospovidone to achieve fast 
disintegration [20] and polyethylene glycol a 
cushioning agent [7] along with magnesium 
stearate as lubricant. Pellet percentage was 
maintained at 30%w/w level based on the 
reported previous studies [21-22].  
 
Tablets were compressed on a single rotary 
compression machine using one set of tooling 
and carefully adjusting the gap between the 
turret and the feed frame to avoid pellet 
entrapment and subsequent physical damage. 
The tablet compressed at an optimum crushing 
strength of 160N was considered and evaluated 
by in vitro drug release studies. Dissolution 
study of six tablets was conducted as per the 
specified method and the release profile was 
compared with the uncompressed pellets. The 
release profile of the MUPS tablets was 




Figure 3: Comparison of in vitro drug release profile 
from (-■-) uncompressed pellets and      (-♦-) compressed 
tablets prepared using sodium alginate 20%w/w and 
treated with calcium chloride solution. 
 
The similarity in the release profile can be due 
to absence of thin film of rate controlling 
polymer as in the case of reservoir type pellets 
which are prone to damage during applied 
compression forces. In our study, each pellet 
was presumed to behave like a monolithic 
matrix mini tablet distributed within the 
cushioning diluent blend. Scanning electron 
micrographs of the segregated pellets from the 
surface of the tablets which are directly exposed 
to the tooling surface were found to be pressed 
in the direction of the applied force (Figure 4A).  
 
 
         
 4A 4B
 
Figure 4: Scanning electron micrographs 4A: Segregated pellets from the tablet surface which are directly exposed to the 
tooling surface during compression and 4B: MUPS tablets containing matrix pellets distributed within the diluent blend. 
 
However, minor physical deformities or change 
in shape is not expected to have significant 
impact on the release profile. This can be 
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uniformly within each pellet cores and 
whenever pellets encounter minor damage 
during compression, polymer within the pellet 
would control the drug release. Hence minimum 
alteration in the drug release from the tablet was 
observed. Achieving such a property is difficult 
in reservoir type pellets where release rate is 
determined directly by the nature and status of 
the polymer film around each pellets.  
 
Scanning electron micrographs (Figure 4B) of 
the tablet showed uniform distribution of the 
pellets as discrete units within the diluent blend 
and remaining separate from each other by 
preventing the fusion and formation of non-
disintegrating matrix mass. Pellets were intact 
and no pellets were found to be fragmented with 
the applied compression force. This was 
possible by keeping the pellet percent at 
30%w/w where individual pellets were well 
separated and protected from the compression 
deformities. 
 
The tablets were compressed at different 
compression forces (2 -6kN) to obtain an 
average crushing strength of 80N to 240N with 
satisfactory physical characteristics. Increasing 
the compression force, increased the hardness 
and disintegration time however, friability was 
decreased (Figure 5). We attribute this 
phenomenon to the formation of more 
condensed compact with increased compression 
force. However, hardness showed no impact on 
the drug release pattern as the tables were 
disintegrating into individual pellets in the 
dissolution vessels. Once the pellets were 
separated, the drug release  pattern obtained 
would be due to the collective contribution from 



















Figure 5: Effect of compression force on tablet 
characteristics, (-♦-) Hardness and (-■-) Disintegration 
time 
 
Content uniformity and Acceptance value 
(AV) 
Content uniformity of the ten compressed tablet 
was evaluated by measuring the sertraline 
content in the individual tablet and Acceptance 
value was calculated. Initial trials were tried 
only using the microcrystalline cellulose (Avicel 
PH 102, 646 mg) and acceptance value was 
found to be 18.7 indicating the poor ability of 
the filler to restrict the selective movement of 
the pellets as reported earlier [23]. However, 
acceptable AV value of 12.2 could be achieved 
by combination of free flowing (PH 102) and 
poorly flowing (PH 101) excipient in the diluent 
blend which might restrict the preferential 
movement of the pellets from the blend into the 
die cavities. Generally, obtaining content 
uniformity is difficult during compression of 
pellets into tablets due to various factors other 
than blend characteristics such as, blend 
residence time, operational equipment 
vibrations, number of tooling installed during 
compression etc. Moreover, when compressing 
the tablets using single punch on a 12 station 
compression machine, the residence time of the 
blend in the feed frame is more and possibility 
for preferential movement of the pellets into the 
die cavity increases leading to variation in the 
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Release Mechanism of drug release 
Higuchi and Korsmeyer-Peppas models were 
commonly applied for understanding the 
dissolution mechanism [24-25] form pellets 
involving diffusion and erosion mechanisms. 
The drug release pattern from the MUPS tablets 
prepared from calcium chloride treated pellets 
containing 20% w/w sodium alginate (#F5) was 
analyzed for drug release kinetics theory by 
plotting the square root of time vs. percent drug 
release and release pattern was linear as per 
Higuchi’s equation (r2= 0.9812). To elucidate 
the possible mechanism, analysis of drug release 
data derived from the dissolution test was fitted 
to the exponential equation. 
Mt/M∞ = k1 . t n                      ……  (2) 
 
Where Mt/M∞ represents the drug dissolved 
fraction at time t; k1 is a constant incorporating 
the structural and geometric characteristics of 
the matrix pellets, n is the release exponent 
indicative of the drug release mechanism. The 
release exponent n value can range between 
0.43 and 1, according to the geometry and the 
prevalence of the Fickian or case II (Relaxation 
transport) mechanism. Though the tablets were 
employed in the dissolution studies, these are 
expected to disintegrate into individual spherical 
pellets in the dissolution media. The lag period 
that pellets remains within the tablet until it 
disintegrates is negligible considering the total 
duration of the release profile. Hence exponent 
n in the Korsmeyer Peppas model for spherical 
particles was considered. For spherical particle,  
n vale between 0.43 and 0.85 indicates 
anomalous type of release involving the 
combination of both diffusion and erosion 
mechanism, when the n value is 0.85, Case II 
type and above 0.85 super case II type release 
mechanism are expected [26]. The release 
component of the calcium chloride treated 
composition showed fair linearity (r2 =0.9824) 
with a slope (n = 0.5161) values, appears to 
indicate the sertraline transport anomalous type. 
The cross-linking property of calcium ions with 
negative charges of alginic acid molecules 
creates an insoluble barrier on the surface 
wherein sertraline initially could diffuse out of 
the pellets through Fickian diffusion followed 
by predominant erosion of polymer for the 
further release of drug during rest of dissolution 
time.  
 
To evaluate and understand the mechanism of 
drug release, the pellets after completing the 
dissolution testing time were observed under 
scanning electron microscope. The pellets were 
carefully collected from the dissolution vessels 
by decanting the media.  These pellets were 
partially dried using laboratory filter papers 
followed by drying at 40 0C in a vacuum oven 
for about a 2 hour. The dried pellets were 
observed under the scanning electron 
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The pellets were found to form sac like structure 
made of insoluble membrane releasing the entire 
content. We presume the drug release from the 
pellets begins with the diffusion followed by 
erosion wherein the weaker part of the insoluble 
gelatinous matrix must have ruptured creating 
the channel and releasing the entire content 
slowly from the matrix core containg sodium 
alginate. This observation justifies the 
theoretically estimated mechanism of drug 
release from the pellets.  
 
Conclusion 
Using various sodium alginate polymer, matrix 
pellets could be successfully prepared. Pellets 
treated with saturated solution of calcium 
chloride extended the drug release up to 12h. 
There was no significant difference in the 
release pattern of MUPS tablet and the 
uncompressed pellets. Acceptance value could 
be well achieved using combination of Avicel 
PH 102 and Avicel PH 101 as fillers in the 
diluent blend. Further, extrusion/spheronization 
technique can be explored to prepare extended 
release matrix type pellets which can be an 
alternative technique to the reservoir type pellets 
in preparing the MUPS tablets. More emphasis 
could be diverted in exploring the other 
techniques to obtain better uniformity of drug 
content in MUPS tablets. 
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